- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension...

CAMBRIDGE, Mass. , May 6, 2021 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its first quarter 2021 financial results before the market opens on Thursday,...

CAMBRIDGE, Mass. , April 16, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering...

CAMBRIDGE, Mass. , April 15, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....

- SYNB1618 demonstrates proof of mechanism and phenylalanine (Phe) consumption in GI tract of healthy volunteers - - SYNB1618 Phase 2 study in patients with PKU ongoing - CAMBRIDGE, Mass. , April 13, 2021   Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative...

- Data demonstrates activation of STING pathway in patients - - Combination arm of Phase 1 study of SYNB1891 ongoing - CAMBRIDGE, Mass. , April 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine,...

CAMBRIDGE, Mass. , April 1, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...

-- SYNB8802 advances to Phase 1B Proof of Concept After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria Study -- -- Synlogic ended 2020 with $100.4 million in cash, cash equivalents, and short-term investments, extending projected runway into 2023 -- -- Management to host conference call...

- 28.6% Urinary Oxalate lowering demonstrated in Dietary Hyperoxaluria in healthy volunteers - - Part B in Enteric Hyperoxaluria patients initiated - CAMBRIDGE, Mass. , March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of...

CAMBRIDGE, Mass. , March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its fourth quarter and full year 2020 financial results before the market opens...

CAMBRIDGE, Mass. , March 8, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Dr. Caroline Kurtz to Chief Development Officer. As Chief Development Officer, Dr....

CAMBRIDGE, Mass. , Feb. 15, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...